Director, Patents
Gridiron Building, 1 Pancras Square, King’s Cross London
N1C 4AG United Kingdom
+442083903775
Unranked
English
Patent
Patent disputes
Patent prosecution
Biotechnology
Chemistry
Life sciences
Medical devices
Pharmaceutical
Stuart is a Chartered UK and European Patent Attorney and Director of Cameron IP specialising in chemistry and life sciences.
He has particular experience in pharmaceuticals, industrial chemistry, chemical engineering, formulation chemistry, medical devices, vaccines, coatings and films, and transdermal patches.
Stuart’s areas of IP expertise include drafting and prosecuting patent applications before the UKIPO and EPO, advising on IP strategies and lifecycle management, and global portfolio management.
He has advised some of the largest corporations in the US and Europe and understands the practical challenges associated with managing portfolios in-house, and the need to work closely with in-house teams, helping them to work within their budgets.
Stuart is also highly experienced in contentious matters, having represented his clients in multiple EPO opposition and appeal proceedings, and in contentious matters before the UKIPO and UK courts. He is an IP Patent Litigator and authorised Unified Patent Court Representative.
He is also an expert in obtaining Supplementary Protection Certificates in Europe.
Stuart regularly attends international IP conferences including APAA and BIO, where he places great importance on meeting with clients and global associates in person, in order to strengthen and deepen relationships. Clients comment that he is a pleasure to work with and that he is very quickly able to distil the essence of a problem.
Stuart assists the Chartered Institute of Patent Attorneys the UK, as the Chair of the Patents Committee, and as a member of a delegation which meets regularly with the UKIPO to discuss practice issues.
He also sits on the Firm’s Operations Board.
Outside of work, Stuart enjoys getting out on his motorbike and spending time with family.
Year joined the firm: 2025